FN075 did not change α-synuclein expression in the AAV-α-synuclein
model
After sacrifice, we sought to determine if AAV-mediated human
α-synuclein overexpression in the nigrostriatal pathway was affected by
subsequent FN075 administration into the striatum. As expected,
immunohistochemical staining confirmed extensive expression of human
α-synuclein throughout the nigrostriatal pathway in groups that received
the overexpression vector (Fig. 2; Substantia nigra: Group,F(3,35) =24.76, p < 0.05;
Striatum: Group, F(3,36) =10.70, p< 0.05), while this was not seen in animals that received the
AAV-GFP vector. However, the density of human α-synuclein
immunohistochemical staining remained unaffected by the α-synuclein
aggregating molecule, FN075, whether this was administered alone or in
conjunction with the AAV-α-synuclein vector.